{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:04:32Z","timestamp":1788519872376,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40273-025-01538-4","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:33:47Z","timestamp":1757388827000},"page":"1271-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["HTA Evidence in Rare Diseases: Just Rare or Also Special?"],"prefix":"10.1007","volume":"43","author":[{"given":"Anirban","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simu K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"1538_CR1","unstructured":"European Commission. Research and innovation: rare diseases. Available from: https:\/\/research-and-innovation.ec.europa.eu\/research-area\/health\/rare-diseases_en. Accessed 20 May 2025."},{"key":"1538_CR2","unstructured":"Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Rare diseases and orphan products: accelerating research and development. In: Field MJ, Boat TF, editors. Rare diseases and orphan products: accelerating research and development. Washington, DC: National Academies Press (US); 2010."},{"issue":"6","key":"1538_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and definitions 2014; a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906\u201314. https:\/\/doi.org\/10.1016\/j.jval.2015.05.008.","journal-title":"Value Health."},{"issue":"2","key":"1538_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"key":"1538_CR5","doi-asserted-by":"publisher","unstructured":"Faye F, Crocione C, Anido de Pena R, Bellagambi S, Escati Penaloza L, Hunter A, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a rare barometer retrospective patient survey. Eur J Hum Genet. 2024;32(9):1116\u201326. https:\/\/doi.org\/10.1038\/s41431-024-01604-z.","DOI":"10.1038\/s41431-024-01604-z"},{"issue":"3","key":"1538_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00056-1","volume":"12","author":"The Lancet Global Health","year":"2024","unstructured":"The Lancet Global Health. The landscape for rare diseases in 2024. Lancet Glob Health. 2024;12(3):e341. https:\/\/doi.org\/10.1016\/S2214-109X(24)00056-1.","journal-title":"Lancet Glob Health"},{"key":"1538_CR7","unstructured":"National Organization for Rare Disorders. Rare disease facts. Available from: https:\/\/cdn.rarediseases.org\/wordpresscontent\/wp-content\/uploads\/2014\/11\/NRD-1008-FactSheet_5.pdf. Accessed 20 May 2025."},{"issue":"5","key":"1538_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrg.2017.116","volume":"19","author":"CF Wright","year":"2018","unstructured":"Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. 2018;19(5):253\u201368. https:\/\/doi.org\/10.1038\/nrg.2017.116.","journal-title":"Nat Rev Genet"},{"issue":"12","key":"1538_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s40273-023-01308-0","volume":"41","author":"DA Marshall","year":"2023","unstructured":"Marshall DA, Gerber B, Lorenzetti DL, MacDonald KV, Bohach RJ, Currie GR. Are we capturing the socioeconomic burden of rare genetic disease? A scoping review of economic evaluations and cost-of-illness studies. Pharmacoeconomics. 2023;41(12):1563\u201388. https:\/\/doi.org\/10.1007\/s40273-023-01308-0.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1538_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","volume":"17","author":"G Yang","year":"2022","unstructured":"Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163. https:\/\/doi.org\/10.1186\/s13023-022-02299-5.","journal-title":"Orphanet J Rare Dis"},{"key":"1538_CR11","unstructured":"Osborne B, Bernitsas E, Taylor N, Zeng F, Anatchkova M, Kielhorn A. Activity impairment and support needs in neuromyelitis optica spectrum disorder: a patient\u2019s perspective. Poster presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 26-28 October, 2022; Amsterdam."},{"key":"1538_CR12","unstructured":"European Medicines Agency. Orphan designation: overview. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/orphan-designation-overview. Accessed 29 Aug 2025."},{"key":"1538_CR13","unstructured":"US Food and Drug Administration. Designating an orphan product: drugs and biological products. Available from: https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/designating-orphan-product-drugs-and-biological-products. Accessed 29 Aug 2025."},{"issue":"5","key":"1538_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jval.2024.12.009","volume":"28","author":"A Gentilini","year":"2025","unstructured":"Gentilini A, Neez E, Wong-Rieger D. Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions. Value Health. 2025;28(5):680\u20135. https:\/\/doi.org\/10.1016\/j.jval.2024.12.009.","journal-title":"Value Health."},{"key":"1538_CR15","unstructured":"European Union. Regulation (EC) No. 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32000R0141. Accessed 20 May 2025."},{"key":"1538_CR16","unstructured":"United States Congress. Rare disease Advancement, surveillance Research, and Education Act of 2022. Available from: https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/9676\/text. Accessed 20 May 2025."},{"issue":"8","key":"1538_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jval.2022.02.006","volume":"25","author":"MF Drummond","year":"2022","unstructured":"Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, et al. Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report. Value Health. 2022;25(8):1257\u201367. https:\/\/doi.org\/10.1016\/j.jval.2022.02.006.","journal-title":"Value Health."},{"issue":"1","key":"1538_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13023-022-02397-4","volume":"17","author":"T Stafinski","year":"2022","unstructured":"Stafinski T, Glennie J, Young A, Menon D. Hta decision-making for drugs for rare diseases: comparison of processes across countries. Orphanet J Rare Dis. 2022;17(1):258. https:\/\/doi.org\/10.1186\/s13023-022-02397-4.","journal-title":"Orphanet J Rare Dis"},{"key":"1538_CR19","unstructured":"National Institute for Health and Care Excellence. PMG37. NICE health technology evaluation topic selection: the manual. 7 Highly specialised technologies. 2022. Available from: https:\/\/www.nice.org.uk\/process\/pmg37\/chapter\/highly-specialised-technologies. Accessed 20 May 2025."},{"key":"1538_CR20","unstructured":"PhRMA. Don\u2019t close the door on rare disease research. 2023. Available from: https:\/\/phrma.org\/blog\/dont-close-the-door-on-rare-disease-research. Accessed 20 May 2025."},{"key":"1538_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2024.101026","volume":"44","author":"P V\u00e1squez","year":"2024","unstructured":"V\u00e1squez P, Hall L, Merlo G. Societal preferences in health technology assessments for rare diseases and orphan drugs: a systematic literature review of new analytic approaches. Value Health Reg Issues. 2024;44:101026. https:\/\/doi.org\/10.1016\/j.vhri.2024.101026.","journal-title":"Value Health Reg Issues"},{"key":"1538_CR22","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/ppa.s416226","volume":"17","author":"Y Gu","year":"2023","unstructured":"Gu Y, Wang A, Tang H, Wang H, Jiang Y, Jin C, et al. Comparison of rare and common diseases in the setting of healthcare priorities: evidence of social preferences based on a systematic review. Patient Prefer Adherence. 2023;17:1783\u201397. https:\/\/doi.org\/10.2147\/ppa.s416226.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1538_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12325-022-02359-z","volume":"40","author":"O Dabbous","year":"2023","unstructured":"Dabbous O, Chachoua L, Aball\u00e9a S, Sivignon M, Persson U, Petrou S, et al. Valuation of treatments for rare diseases: a systematic literature review of societal preference studies. Adv Ther. 2023;40(2):393\u2013424. https:\/\/doi.org\/10.1007\/s12325-022-02359-z.","journal-title":"Adv Ther"},{"issue":"1","key":"1538_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12501","volume":"11","author":"HJS Dawkins","year":"2018","unstructured":"Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in rare diseases research 2010\u20132016: an IRDiRC perspective. Clin Transl Sci. 2018;11(1):11\u201320. https:\/\/doi.org\/10.1111\/cts.12501.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1538_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13023-014-0195-4","volume":"10","author":"ED Kakkis","year":"2015","unstructured":"Kakkis ED, O\u2019Donovan M, Cox G, Hayes M, Goodsaid F, Tandon PK, et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J Rare Dis. 2015;10(1):16. https:\/\/doi.org\/10.1186\/s13023-014-0195-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1538_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-023-02667-9","volume":"18","author":"M Gittus","year":"2023","unstructured":"Gittus M, Chong J, Sutton A, Ong ACM, Fotheringham J. Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review. Orphanet J Rare Dis. 2023;18(1):140. https:\/\/doi.org\/10.1186\/s13023-023-02667-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1538_CR27","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1017\/S026646232400062X","volume":"40","author":"P Kranz","year":"2024","unstructured":"Kranz P, McGauran N, Unal C, Kaiser T. Results of health technology assessments of orphan drugs in Germany: lack of added benefit, evidence gaps, and persisting unmet medical needs. Int J Technol Assess Health Care. 2024;40(1):e68. https:\/\/doi.org\/10.1017\/S026646232400062X.","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"1538_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2117175.","journal-title":"N Engl J Med"},{"key":"1538_CR29","unstructured":"Canada\u2019s Drug Agency. Guidelines for the economic evaluation of health technologies: Canada. 2021. Available from: https:\/\/www.cda-amc.ca\/guidelines-economic-evaluation-health-technologies-canada-0. Accessed 20 May 2025."},{"key":"1538_CR30","unstructured":"IQWiG. General methods version 6.1 of 24 January 2022. Available from: https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-1.pdf. Accessed 20 May 2025."},{"key":"1538_CR31","unstructured":"National Institute for Health and Care Excellence. PMG36. NICE health technology evaluations: the manual. 2022. Available from: www.nice.org.uk\/process\/pmg36. Accessed 20 May 2025."},{"issue":"6","key":"1538_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","volume":"33","author":"KJ Ishak","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537\u201349. https:\/\/doi.org\/10.1007\/s40273-015-0271-1.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1538_CR33","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"1538_CR34","unstructured":"International Rare Diseases Research Consortium. Patient-centered outcome measures initiatives in the field of rare diseases. 2016. Available from: https:\/\/www.irdirc.org\/wp-content\/uploads\/2017\/12\/PCOM_Post-Workshop_Report_Final.pdf. Accessed 20 May 2025."},{"issue":"1","key":"1538_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61. https:\/\/doi.org\/10.1186\/s13023-018-0810-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1538_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40271-020-00493-w","volume":"14","author":"A Whittal","year":"2021","unstructured":"Whittal A, Meregaglia M, Nicod E. The use of patient-reported outcome measures in rare diseases and implications for health technology assessment. Patient. 2021;14(5):485\u2013503. https:\/\/doi.org\/10.1007\/s40271-020-00493-w.","journal-title":"Patient"},{"key":"1538_CR37","unstructured":"National Institute for Health and Care Excellence. Technology appraisal guidance TA1003: exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over. 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1003\/. Accessed 20 May 2025."},{"issue":"4","key":"1538_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","volume":"123","author":"P Harmatz","year":"2018","unstructured":"Harmatz P, Whitley CB, Wang RY, Bauer M, Song W, Haller C, et al. A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488\u201394. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.006.","journal-title":"Mol Genet Metab"},{"key":"1538_CR39","unstructured":"US Food and Drug Administration. Individualized endpoints in pediatric rare disease trials: a clinical perspective. 2019. Available from: https:\/\/www.fda.gov\/media\/133753\/download. Accessed 29 Aug 2025."},{"key":"1538_CR40","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. Application number 761047Orig1s000. Clinical review(s). 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761047Orig1s000MedR.pdf. Accessed 29 Aug 2025."},{"key":"1538_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106704","volume":"114","author":"JL Neul","year":"2022","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022;114:106704. https:\/\/doi.org\/10.1016\/j.cct.2022.106704.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"1538_CR42","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med. 2023;29(6):1468\u201375. https:\/\/doi.org\/10.1038\/s41591-023-02398-1.","journal-title":"Nat Med"},{"issue":"8","key":"1538_CR43","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1469-7610.00236","volume":"43","author":"RH Mount","year":"2002","unstructured":"Mount RH, Charman T, Hastings RP, Reilly S, Cass H. The rett syndrome behaviour questionnaire (RSBQ): refining the behavioural phenotype of rett syndrome. J Child Psychol Psychiatry. 2002;43(8):1099\u2013110. https:\/\/doi.org\/10.1111\/1469-7610.00236.","journal-title":"J Child Psychol Psychiatry"},{"issue":"3","key":"1538_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40273-023-01321-3","volume":"42","author":"E Henry","year":"2024","unstructured":"Henry E, Al-Janabi H, Brouwer W, Cullinan J, Engel L, Griffin S, et al. Recommendations for emerging good practice and future research in relation to family and caregiver health spillovers in health economic evaluations: a report of the SHEER task force. Pharmacoeconomics. 2024;42(3):343\u201362. https:\/\/doi.org\/10.1007\/s40273-023-01321-3.","journal-title":"Pharmacoeconomics"},{"key":"1538_CR45","unstructured":"Bundesgesetzblatt. Gesetz zur finanziellen Stabilisierung der gesetzlichen Krankenversicherung (GKV-Finanzstabilisierungsgesetz). 2022. Available from: https:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl122s1990.pdf#\/text\/bgbl122s1990.pdf?_ts=1747751976782. Accessed 20 May 2025."},{"key":"1538_CR46","unstructured":"IQWiG. Preis\u2010 und Kostenentwicklung von Orphan Drugs. Arbeitspapier. 2024. Available from: https:\/\/www.iqwig.de\/download\/ga22-01_preisund-kostenentwicklung-von-orphan-drugs_arbeitspapier_v1-0.pdf. Accessed 20 May 2025."},{"issue":"1","key":"1538_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2297746","volume":"56","author":"AB Abel","year":"1989","unstructured":"Abel AB, Mankiw NG, Summers LH, Zeckhauser RJ. Assessing dynamic efficiency: theory and evidence. Rev Econ Stud. 1989;56(1):1\u201319. https:\/\/doi.org\/10.2307\/2297746.","journal-title":"Rev Econ Stud"},{"issue":"2","key":"1538_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jval.2024.10.3848","volume":"28","author":"A Basu","year":"2025","unstructured":"Basu A. Financial impacts of paying for gene therapy for sickle cell disease under alternative pricing and financing mechanisms. Value Health. 2025;28(2):233\u201340. https:\/\/doi.org\/10.1016\/j.jval.2024.10.3848.","journal-title":"Value Health"},{"issue":"4","key":"1538_CR49","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/hec.4795","volume":"33","author":"B Woods","year":"2024","unstructured":"Woods B, Lomas J, Sculpher M, Weatherly H, Claxton K. Achieving dynamic efficiency in pharmaceutical innovation: identifying the optimal share of value and payments required. Health Econ. 2024;33(4):804\u201319. https:\/\/doi.org\/10.1002\/hec.4795.","journal-title":"Health Econ"},{"key":"1538_CR50","unstructured":"IQVIA. EFPIA Patients W.A.I.T. Indicator 2022 Survey. 2023. Available from: https:\/\/www.efpia.eu\/media\/s4qf1eqo\/efpia_patient_wait_indicator_final_report.pdf. Accessed 20 May 2025."},{"key":"1538_CR51","unstructured":"European Union. Document 32021R2282. Regulation (EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011\/24\/EU. 2021. Available from: https:\/\/eur-lex.europa.eu\/eli\/reg\/2021\/2282\/oj. Accessed 29 Aug 2025."},{"issue":"1","key":"1538_CR52","doi-asserted-by":"publisher","DOI":"10.1017\/s0266462323000338","volume":"39","author":"RA Vreman","year":"2023","unstructured":"Vreman RA, van Hoof D, Nachtnebel A, Daems J, van de Casteele M, Fogarty E, et al. The Beneluxa initiative domain task force health technology assessment: a comparison of member countries\u2019 past health technology assessments. Int J Technol Assess Health Care. 2023;39(1):e44. https:\/\/doi.org\/10.1017\/s0266462323000338.","journal-title":"Int J Technol Assess Health Care"},{"issue":"9","key":"1538_CR53","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.healthpol.2020.06.013","volume":"124","author":"F Chassagnol","year":"2020","unstructured":"Chassagnol F, Marcelli G, Wagle J, Giuliani G, Traub D, Schaub V, et al. Review of relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): a first step towards a consolidated European perspective on comparative effectiveness & safety? Health Policy. 2020;124(9):943\u201351. https:\/\/doi.org\/10.1016\/j.healthpol.2020.06.013.","journal-title":"Health Policy"},{"key":"1538_CR54","unstructured":"EUnetHTA. European Network for Health Technology Assessment Joint Action 3, 2016-2021. Available from: https:\/\/health.ec.europa.eu\/document\/download\/8173ce3b-37e1-41b2-abd0-66dbc47df6e3_en. Accessed 29 Aug 2025."},{"key":"1538_CR55","unstructured":"Joint Nordic HTA Bodies: JNHB. Available from: https:\/\/jnhtabodies.org\/about\/. Accessed 8 Aug 2025."},{"key":"1538_CR56","unstructured":"EveryLife Foundation. The National Economic Burden of Rare Disease Study. 2021. Available from: https:\/\/everylifefoundation.org\/wp-content\/uploads\/2021\/02\/The_National_Economic_Burden_of_Rare_Disease_Study_Summary_Report_February_2021.pdf. Accessed 20 May 2025."},{"key":"1538_CR57","unstructured":"National Institute for Health and Care Excellence. Managed access. 2024. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/managed-access. Accessed 20 May 2025."},{"key":"1538_CR58","unstructured":"NHS England. Cancer Drugs Fund. Available from: https:\/\/www.england.nhs.uk\/cancer\/cdf\/. Accessed 29 Aug 2025."},{"key":"1538_CR59","unstructured":"NHS England. Innovative Medicines Fund. Available from: https:\/\/www.england.nhs.uk\/medicines-2\/innovative-medicines-fund. Accessed 29 Aug 2025."},{"key":"1538_CR60","volume-title":"Cost-effectiveness in health and medicine","author":"Second Panel on Cost-Effectiveness in Health and Medicine","year":"2016","unstructured":"Second Panel on Cost-Effectiveness in Health and Medicine. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 2016."},{"issue":"6","key":"1538_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40273-024-01370-2","volume":"42","author":"TS Grand","year":"2024","unstructured":"Grand TS, Ren S, Hall J, Astrom DO, Regnier S, Thokala P. Issues, Challenges and opportunities for economic evaluations of orphan drugs in rare diseases: an umbrella review. Pharmacoeconomics. 2024;42(6):619\u201331. https:\/\/doi.org\/10.1007\/s40273-024-01370-2.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1538_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14737167.2019.1633918","volume":"19","author":"P Lasalvia","year":"2019","unstructured":"Lasalvia P, Prieto-Pinto L, Moreno M, Castrillon J, Romano G, Garzon-Orjuela N, et al. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):409\u201320. https:\/\/doi.org\/10.1080\/14737167.2019.1633918.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01538-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01538-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01538-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:41:52Z","timestamp":1760715712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01538-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01538-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB has engaged in private consulting work through Salutis Consulting LLC outside of the submitted work. RC is an employee of the Center for Innovation & Value Research. The Center supports its work via general funds from unrestricted membership fees. Members are listed at:\n                      \n                      . Members with interests in rare disease include Alexion AstraZeneca Rare Disease, Amgen, BIO, Boehringer Ingelheim, Bristol Myers Squibb, Dravet Syndrome Foundation, GSK, Johnson & Johnson, Eli Lilly, EveryLife Foundation for Rare Diseases, Foundation for Sarcoidosis Research, Genentech, Gilead, International Rett Syndrome Foundation, Merck, National Organization for Rare Disorders (NORD), Novartis, Otsuka, Pfizer, Takeda, and UCB. JS declares no competing interests. ST is an employee of Alexion, AstraZeneca, and holds stock or stock options in AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}